Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Advancing Restart of Beacon Gold Mill and Bulk Sample for Swanson Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GRI Bio Inc GRI

Healthcare Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis... see more

Recent & Breaking News (NDAQ:GRI)

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

GlobeNewswire May 22, 2025

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire May 21, 2025

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GlobeNewswire May 16, 2025

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GlobeNewswire May 15, 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") 

GlobeNewswire May 8, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

GlobeNewswire May 7, 2025

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GlobeNewswire April 16, 2025

GRI Bio Announces Closing of $5.0 Million Public Offering

GlobeNewswire April 2, 2025

GRI Bio Announces Pricing of $5.0 Million Public Offering

GlobeNewswire April 1, 2025

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

GlobeNewswire April 1, 2025

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GlobeNewswire March 31, 2025

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GlobeNewswire March 18, 2025

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

GlobeNewswire March 17, 2025

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GlobeNewswire March 11, 2025

GRI Bio Announces Reverse Stock Split

GlobeNewswire February 19, 2025

GRI Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

GlobeNewswire February 19, 2025

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GlobeNewswire December 23, 2024

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire December 6, 2024

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire November 21, 2024

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GlobeNewswire November 14, 2024